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Introduction 
Hidradenitis suppurativa (HS) is characterized by 
recurrent abscesses, persistent pain, sinus tract 
formation, and scarring. This disorder has 
multifaceted clinical features and an unpredictable 
disease course that can make management 
challenging. Hidradenitis suppurativa shares several 
clinical features and pathogenic links with Crohn 
disease (CD), and observational studies have 
suggested they are linked [1, 2]. Herein, we report a 
patient with severe HS and CD that was refractory to 
multiple treatments but responded well to 
combination adalimumab/ ustekinumab. 
 
Case Synopsis 
A 39-year-old woman presented for evaluation of HS 
in the setting of Crohn disease of the both the small 
and large intestine (CD). The patient had HS Hurley 
stage III of the axilla, groin, and medial thighs for 
several years. Past treatments for HS included 
rifampin and spironolactone, which had no effect. 
Past treatment for her CD included adalimumab, 
methotrexate, mesalamine, infliximab, azathioprine, 
golimumab, certolizumab pegol, and multiple 
surgeries. The patient reported limited benefit or 
adverse side effects to many medications used to 
treat CD. Most recently, the patient started on 
ustekinumab for CD. During evaluation for HS, the 
patient reported that she had good control of her HS 
when she was using adalimumab for CD. 
Discussion with her gastroenterologist led to a 
regimen of adalimumab for HS and ustekinumab for 
CD. The patient started on adalimumab 80mg 
loading dose, followed by 40mg weekly, and 
ustekinumab 90mg every 8 weeks. The patient 
followed-up in clinic two months after starting the 
loading dose. 
At the follow-up visit, the patient report clear 
improvement in her HS with the combined therapy. 
She reported tolerating the medication well with no 
side effects or recently infections. Physical 
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examination demonstrated small draining nodules 
in the bilateral axillae as well as scarring and sinus 
tract formation; however, this was much improved 
from her previous encounter (Figure 1). The patient 
continues on adalimumab and ustekinumab without 
complaint. 
 
Case Discussion 
The association of CD and HS has garnered attention. 
A recent paper observed a prevalence of 2% for CD 
among HS patients, with HS patients three times 
more likely to have CD than those without HS [3]. 
Hidradenitis suppurativa and CD are both associated 
with significant physical and psychological 
morbidity, as well as difficult management issues. 
Biological agents, including tumor necrosis factor 
inhibitors are approved to treat both conditions. The 
benefit of adalimumab for HS was first reported in a 
patient with inflammatory bowel disease and  
concomitant HS [4]. However, paradoxical HS has 
been reported in patients with inflammatory bowel 
disease treated with adalimumab [5, 6]. 
 
Conclusion 
Currently, HS remains a difficult disease to treat with 
great unmet medical needs for moderate and severe 
forms. To our knowledge, this is the first cas of 
effective treatment of HS in the setting of CD with 
combination adalimumab and ustekinumab. 
Although a patient’s insurance may hesitate to 
approve the use of two biological medications for 
treatment, we hope this case may help guide future 
management of similarly difficult cases. 
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Figure 1. Clinical response of bilateral axillae to adalimumab and ustekinumab combination therapy A) before, and B) after treatment.
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